Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. Asp-8273
2. Asp8273
1. 1448232-80-1
2. Asp8273
3. Naquotinib [usan]
4. Asp-8273
5. 2-pyrazinecarboxamide, 6-ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3r)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-
6. 47dd4548pb
7. 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3r)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide
8. (r)-5-((1-acryloylpyrrolidin-3-yl)oxy)-6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrazine-2-carboxamide
9. 2-pyrazinecarboxamide, 6-ethyl-3-((4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-(((3r)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl)oxy)-
10. E-2-carboxamide
11. Naquotinib [inn]
12. Naquotinib (usan/inn)
13. Asp8273 (naquotinib)
14. Naquotinib; Asp-8273
15. Naquotinib [who-dd]
16. Unii-47dd4548pb
17. Gtpl9248
18. Chembl3663929
19. Schembl16196078
20. Bdbm170514
21. Ex-a2669
22. Yhc23280
23. Nsc793322
24. S8412
25. Zinc205341959
26. Ccg-270060
27. Cs-5469
28. Db12036
29. Nsc-793322
30. Ac-35709
31. As-75247
32. Hy-19729
33. J3.496.214f
34. A14408
35. C91356
36. D10958
37. Us9085540, 54
38. A857977
39. Q27074546
40. 5-[[(3r)-1-acryloylpyrrolidine-3-yl]oxy]-6-ethyl-3-[4-[4-(4-methylpiperazine-1-yl)piperidino]anilino]pyrazine-2-carboxamide
41. 6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-(((3r)-1-(1-oxoprop-2-en-1-yl)pyrrolidin-3-yl)oxy)pyrazine-2-carboxamide
42. 6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-{[(3r)-1-(prop-2-enoyl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide
43. 6-ethyl-3-(4-(4-(4-methylpiperazin-1-yl)piperidin- 1-yl)anilino)-5-(((3r)-1-(prop-2-enoyl)pyrrolidin- 3-yl)oxy)pyrazine-2-carboxamide
44. 6-ethyl-3-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)anilino)-5-(((3r)-1-(prop-2-enoyl)pyrrolidin-3-yl)oxy)pyrazine-2-carboxamide
45. 6-ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3r)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-2-pyrazinecarboxamide
46. 6-ethyl-3-[[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-[(3r)-1-prop-2-enoylpyrrolidin-3-yl]oxy-pyrazin
| Molecular Weight | 562.7 g/mol |
|---|---|
| Molecular Formula | C30H42N8O3 |
| XLogP3 | 3.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Exact Mass | 562.33798723 g/mol |
| Monoisotopic Mass | 562.33798723 g/mol |
| Topological Polar Surface Area | 120 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 883 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
ABOUT THIS PAGE
40
PharmaCompass offers a list of Naquotinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Naquotinib manufacturer or Naquotinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Naquotinib manufacturer or Naquotinib supplier.
PharmaCompass also assists you with knowing the Naquotinib API Price utilized in the formulation of products. Naquotinib API Price is not always fixed or binding as the Naquotinib Price is obtained through a variety of data sources. The Naquotinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Naquotinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Naquotinib, including repackagers and relabelers. The FDA regulates Naquotinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Naquotinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Naquotinib supplier is an individual or a company that provides Naquotinib active pharmaceutical ingredient (API) or Naquotinib finished formulations upon request. The Naquotinib suppliers may include Naquotinib API manufacturers, exporters, distributors and traders.
Naquotinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Naquotinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Naquotinib GMP manufacturer or Naquotinib GMP API supplier for your needs.
A Naquotinib CoA (Certificate of Analysis) is a formal document that attests to Naquotinib's compliance with Naquotinib specifications and serves as a tool for batch-level quality control.
Naquotinib CoA mostly includes findings from lab analyses of a specific batch. For each Naquotinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Naquotinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Naquotinib EP), Naquotinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Naquotinib USP).